Today, the subscription period begins in Spago Nanomedical’s rights issue
Today, the subscription period begins in Spago Nanomedical AB's (publ) rights issue of shares of up to SEK 61.8 million (the "Rights Issue"), as resolved by the Board with the support of the authorization received at the Annual General Meeting on May 18, 2022.
The rights issue comprises a maximum of 51,477,858 shares. Shareholders in Spago Nanomedical on the record date, June 9, 2022, have a preferential right to subscribe for shares in the Rights Issue. Each shareholder receives one (1) subscription right for each share held on the record date. Four (4) subscription rights entitle the shareholders to subscribe for five (5) new shares in the Company. The subscription price is SEK 1.20 per share. Also, individuals not currently shareholders have the opportunity to register an interest in the Rights issue.
- June 13 – June 22, 2022 – Trading in subscription rights
- June 13 – June 28, 2022 – Subscription period
- 1 July 2022 – Estimated date for publication of the outcome of the Rights Issue
The prospectus, containing complete terms and instructions, is available on the Company's, Erik Penser Bank's and Finansinspektionen's websites respectively (www.spagonanomedical.se, www.penser.se, www.fi.se). Application forms are available on the Company's and Erik Penser Bank's respective websites.
Today, the Company's CEO Mats Hansen presents the Company's operations and future plans at “Småbolagsdagarna” at 6.30 pm. The presentation can be viewed at the following link: https://www.aktiespararna.se/tv/live. The company also publishes an interview with CEO Mats Hansen in connection with the Rights Issue. In the interview, Mats Hansen goes through, among other things, what the net proceeds will be used for and provides a project update on SpagoPix and Tumorad. The interview can be reached at the following link https://youtu.be/9gdYS5AIzXI. More presentations and interviews with the Company can be seen on the Company's website at the following link https://spagonanomedical.se/videos/video-category/presentations/.
Erik Penser Bank is the financial advisor and Cederquist is the legal advisor to Spago Nanomedical in connection with the Rights Issue.